Gantner Dashiell, Moore Elizabeth M, Cooper D James
aAustralian and New Zealand Intensive Care Research Centre, Monash University bCentre of Excellence in Traumatic Brain Injury Research, Monash University, The Alfred Hospital cDepartment of Intensive Care, The Alfred Hospital, Melbourne, Victoria, Australia.
Curr Opin Crit Care. 2014 Aug;20(4):385-9. doi: 10.1097/MCC.0000000000000114.
Intravenous fluid is a fundamental component of trauma care and fluid management influences patient outcomes. This narrative review appraises recent clinical studies of fluid therapy in patients with traumatic brain injury (TBI), with respect to its use in volume resuscitation and prevention of secondary injury.
Despite the development of level 1 evidence in fluid resuscitation, in patients with TBI key questions concerning optimal composition and volume remain unanswered. In the absence of randomized trials demonstrating patient outcome differences, clinical practice is often based on physiological principles and surrogate endpoints. There is a physiological rationale why excessive fluid administration and positive fluid balance may increase brain swelling and intracranial pressure (ICP); in some patients, a lower cumulative fluid balance may improve outcomes, but limited human data exist. Resuscitation with 4% albumin in TBI patients in ICU worsens mortality, which may be mediated by increased ICP during the first week after injury. Hypertonic saline and mannitol decrease ICP, but may not improve survival or neurological outcomes. Sodium lactate may be a future therapy for treatment and prevention of secondary brain injury.
In patients with TBI, intravenous fluids are integral to management; they may be both a source of harm and a potential therapy to limit secondary brain injury. They should be prescribed in accordance with other pharmaceutical or therapeutic interventions. Refined usage may improve patient outcomes.
静脉输液是创伤治疗的基本组成部分,液体管理会影响患者的预后。本叙述性综述评估了创伤性脑损伤(TBI)患者液体治疗的近期临床研究,涉及液体在容量复苏及预防继发性损伤中的应用。
尽管在液体复苏方面已有一级证据,但对于TBI患者,关于最佳成分和容量的关键问题仍未得到解答。在缺乏显示患者预后差异的随机试验的情况下,临床实践通常基于生理学原理和替代终点。从生理学角度来看,过量输液和正液体平衡为何会增加脑肿胀和颅内压(ICP)是有原因的;在一些患者中,较低的累积液体平衡可能会改善预后,但相关人体数据有限。在ICU中,对TBI患者使用4%白蛋白进行复苏会增加死亡率,这可能是由受伤后第一周内ICP升高介导的。高渗盐水和甘露醇可降低ICP,但可能无法改善生存率或神经功能预后。乳酸钠可能是未来治疗和预防继发性脑损伤的一种疗法。
对于TBI患者,静脉输液是治疗的重要组成部分;它们可能既是伤害的来源,也是限制继发性脑损伤的潜在疗法。应根据其他药物或治疗干预措施来开具静脉输液处方。优化使用可能会改善患者预后。